Mirxes Holding Co., Ltd. operates as an investment holding company. It engages in the developing and commercializing blood-based miRNA test kit products for the early detection of cancer and other diseases. The firm’s business segments include Early Detection and Precision Multi-Omics; and Infectious Diseases. The Early Detection and Precision Multi-Omics involves in development, manufacture, supply of diagnostic and life sciences products, and provision of research profiling, clinical testing and clinical services. The Infectious Diseases segment engages in development, manufacture, supply of diagnostic kits, and provision of infectious disease clinical testing. The company was founded by Too Heng Phon, Zhou Lihan, and Zou Ruiyang in 2014 and is headquartered in Singapore.